Why Are So Many Of You Buying Into The GLP-1 Hype?

It feels like you can’t escape the buzz around GLP-1 drugs on LinkedIn. Between the media headlines, excited investors, and viral social media posts, you’d think we’ve found a medical miracle. Ozempic, Wegovy, Mounjaro—they’re household names now. With all this excitement, are we missing the bigger picture? Why is everyone so focused on the miracle without talking about the catches? The answer tells us a lot about the drugs, but maybe even more about people who work in healthcare who are clueless.

First, let’s be clear: these drugs work. The results from clinical trials are stunning, showing people can lose 15% or more of their body weight. For many, that’s life-changing.

But here’s the fine print you don’t see on LinkedIn: the weight often comes right back when you stop taking them. In fact, studies show that people can regain two-thirds of the weight they lost just a year after stopping the medication. This isn’t a quick fix; for most, it’s a lifelong commitment. And that reality, which is often glossed over, changes everything when you think about the cost and risks involved.

Then there’s the price tag and lingering side effects, which nobody seems to want to talk about. These drugs are incredibly expensive, often running over $1,000 a month. While some insurance plans are starting to cover them, many people are still stuck with huge bills. Now, employers and insurers are getting nervous, wondering how they can possibly afford to cover these drugs for millions of people, forever. The side effects, which I have experienced personally, are horrible: loss of muscle mass and a constant feeling of nausea. What many people are learning is that even with weight loss, you just feel better without taking a GLP-1.

People in healthcare people also need to be honest about whether people can even stick with these drugs long-term. The reality is, a lot of people stop taking them within the first year. The side effects—nausea, vomiting, just feeling sick to your stomach—can be brutal. This creates a frustrating cycle: start the drug, lose weight, feel awful, stop the drug, and then watch the weight come back. You don’t hear that story very often when these are being pitched as a cure-all.

So why does the hype persist? Part of it is cultural, part is people trying to impress us on LinkedIn. We love a simple solution to a complicated problem. Obesity is a tangled mess of genetics, diet, environment, and economics. A weekly injection is just a much easier story to sell than a tough conversation about food systems and lifestyle changes.

And it’s not just an easy sell—it’s an incredibly profitable one. Analysts think the market for these drugs could top $100 billion a year. With that much money on the line, is it any surprise the nuance is getting drowned out?

Look, none of this is to say these drugs aren’t a huge medical advancement. They are. For many people, they are truly life-saving. But the conversation on LinkedIn about them is dangerously one-sided. We’re not talking enough about the rebound weight, the staggering long-term cost, the constant shortages, or how many people just can’t tolerate the side effects. Too often, people in our industry post to try to show their “smarts,” but in reality, they are drug company pawns.

These drugs are a powerful tool in the toolbox, but they aren’t a silver bullet. No single drug can solve a problem this complex on its own. Until we can have a more balanced conversation, the hype will continue to run way ahead of reality.

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply